TORONTO, Sept. 28 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced
today that Dr. Andre Uddin, President of BioStratgy Management Inc. has been
hired to evaluate new strategic initiatives and help build shareholder value.
This partnership was formed in an effort to enhance Microbix's relationships
with the institutional investment community. "We are excited to have Dr. Uddin
on board as we enter the next growth phase for Microbix," commented William J.
Gastle, Chairman and CEO of Microbix, "BioStrategy Management will enhance our
ability to communicate our unique message to the institutional community as we
focus on forming strategic alliances to get our innovative products to
Dr. Uddin, was a top ranked analyst specializing in coverage of the
Canadian biotechnology, pharmaceutical and medical device sectors. Dr. Uddin
has held senior biotechnology and pharmaceutical analyst positions at National
Bank Financial, Research Capital and Merrill Lynch Canada. Dr. Uddin holds an
Honours Bachelor of Science (B.Sc.) degree in BioChemistry from the University
of Toronto and a Doctor of Philosphy (Ph.D.) in Biological Chemistry from
"The management team of Microbix has built a solid company which I
believe has the potential to join the Canadian list of elite biotechnology
companies that are profitable. What is unique to Microbix is that the
company's base business has been generating a steady stream of cash flow
providing a platform to help finance its large market products. All three of
these products are approaching commercialization with growing partnering
interest. Given this promising outlook, BioStrategy Management looks forward
to helping build shareholder value for Microbix," said Dr. Andre Uddin.
The Company's major pipeline products include: its VIRUSMAX(TM)
Technology which significantly boosts the yield of influenza virus from eggs
and can help address the current global flu vaccine capacity issue; Urokinase,
a thrombolytic biologic that can be used as a catheter clearing drug and has
potential in new cancer drug combination; and its Semen Sexing Technology(TM)
which can ensure the sex of livestock offspring resulting from artificial
"With his ten years of extensive capital market experience and strong
scientific background, Dr. Uddin will be a tremendous asset to our Company as
he is highly respected by the institutional investment community and
biotechnology companies. He will significantly help raise the profile of our
company," said Mr. Gastle.
Microbix specializes in developing proprietary biological technologies
and commercializing them through global partners. Established in 1988,
Microbix is headquartered in Toronto.
BioStrategy Management Inc. is a premier management consultancy firm
serving the biotechnology, medical device and pharmaceutical industries.
This press release contains forward-looking statements, which are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements. These
forward-looking statements represent the Company's judgment as of the date of
this press release. The Company disclaims any intent or obligation to update
these forward-looking statements.
For further information:
For further information: visit www.microbix.com or contact: William J.
Gastle, CEO, Microbix Biosystems Inc., (416) 234-1624 x 230; Dr. Andre Uddin,
President, BioStrategy Management Inc., www.biostrategymanagement.com, (289)
891-9569; Robert Stephens, PR POST, (416) 777-0368